Align Names Former P&G Healthcare Chief Jennifer Davis as Next CEO

Align Technology has appointed Jennifer L. Davis as its next president and chief executive officer, setting up the first CEO transition at the digital-dentistry company in more than a decade.

Davis will join as CEO-elect and a director on November 2, 2026, and assume the president and CEO roles on December 31. She succeeds Joseph Hogan, who has led the company since 2015. Hogan will become a strategic advisor after stepping down and is expected to remain on the board until its June 2027 strategy meeting.

Davis spent 33 years at Procter & Gamble and most recently led its global healthcare business, a multibillion-dollar portfolio that included oral-health and personal-health brands. The appointment gives the company a leader with experience in consumer healthcare, brand development, commercialization and operating large global businesses.

The transition comes as the business is balancing growth in clear aligners with weaker dental-equipment demand. Third-quarter revenue was $1.015 billion, up 1.9% from a year earlier. Clear-aligner revenue increased 4.2% to $839.3 million, and case volume rose 6.6% to 690,600. Imaging systems and CAD/CAM services revenue fell 7.6% to $175.5 million.

Management said North American orthodontist shipments increased year over year for the first time in six quarters, while DSO shipments grew at a double-digit rate across orthodontist and general-practice customers. Scanner placements—including purchased, leased, rented and certified pre-owned units—also increased at a double-digit rate, taking the installed base above 157,000 systems globally.

Those figures provide important context for the leadership change. The core aligner franchise is growing, but the capital-equipment business remains exposed to cautious practice spending. Davis will inherit a portfolio that spans Invisalign, iTero scanners, exocad software and an expanding set of digital and direct-fabrication workflows.

Why it matters

This is more than a routine executive appointment because the company sits at the intersection of consumer demand, clinical adoption and dental technology infrastructure. Its products influence orthodontic treatment, intraoral scanning, restorative workflows, laboratory software and purchasing decisions across individual practices and DSOs.

Davis's background suggests the board values commercialization and consumer-healthcare experience alongside technical innovation. That could matter as the company tries to increase treatment demand, broaden general-dentist adoption and turn its installed scanner base into more recurring digital workflow activity. It does not, by itself, confirm a shift in strategy.

The operating backdrop also highlights the split within dental technology. Software, treatment volume and workflow adoption can grow while large equipment purchases remain pressured. Avized's Q3 2026 dental technology review documents a market in which investment continues, but buyers increasingly demand measurable operating value rather than broad AI or platform claims.

For DSOs, the transition matters because the company is a major enterprise counterparty across scanners, aligners and software. Large groups will watch whether the new leadership changes product packaging, fleet economics, enterprise agreements, training, consumer marketing or interoperability policy.

The broader 2026 dental technology market map shows how scanner, CAD/CAM, treatment-planning and practice-software categories are converging. A company controlling several layers of that workflow can create meaningful efficiency, but it also increases the importance of data access, contract structure and ecosystem flexibility.

That interoperability question is especially relevant after the Ninth Circuit recently revived antitrust claims tied to the end of Invisalign compatibility with rival TRIOS scanners. Avized's analysis of the interoperability case explains why integration policy can affect the economics of equipment purchases. The appellate ruling did not establish liability, but the litigation remains part of the environment the next CEO will manage.

What to watch next

Strategic priorities after December 31. The first useful signals will come from capital allocation, product-roadmap emphasis, leadership appointments and how management describes the balance between clinical innovation, consumer demand generation and enterprise adoption.

Scanner recovery. Unit placements increased, but imaging and CAD/CAM revenue declined. Buyers should watch whether leasing, rentals and certified pre-owned programs expand access while pressuring average selling prices or changing upgrade cycles.

DSO commercial strategy. Double-digit shipment growth to DSO customers makes enterprise contracting an important test. Watch for changes in volume programs, cross-product bundles, fleet management, training and data integration.

Direct fabrication. Management highlighted its NXT materials platform and new direct-printed applications, including attachments and a U.S. pilot for a custom sports mouth guard. The key question is whether these products become scalable clinical workflows rather than isolated launches.

Consumer and doctor adoption. Davis's experience could support stronger brand and demand-generation programs. The operating test will be whether those efforts increase doctor utilization and completed cases without weakening practice economics.

Interoperability and legal risk. The next leadership team will have to manage platform expansion while the remanded antitrust litigation proceeds. Contract terms, integration decisions and the treatment of third-party workflows deserve close attention.

The appointment gives one of dentistry's most influential technology companies a leader with deep consumer-healthcare experience at a time when clinical platforms are becoming broader and more interconnected. Its significance will be determined by execution: product adoption, scanner economics, DSO relationships and how the company balances a vertically integrated ecosystem with customer demand for flexibility.

Primary sources

• Company announcement — CEO succession plan, October 28, 2026
• Form 8-K — CEO appointment and transition terms, filed October 28, 2026
• Third-quarter 2026 financial results, October 28, 2026